Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study.

Ursula A Matulonis Domenica Lorusso Ana Oaknin Sandro Pignata Andrew Dean Hannelore G Denys Nicoletta Colombo Toon Van Gorp Jason A Konner Margarita Romeo Marin Philipp HarterConleth G MurphyJiuzhou WangElizabeth NobleBrooke EstevesMichael MethodRobert L Coleman

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

MIRV demonstrated consistent clinically meaningful antitumor activity and favorable tolerability and safety in patients with FRα-high PROC who had received up to three prior therapies, including bevacizumab, representing an important advance for this biomarker-selected population.

Keyphrases

poor prognosis
open label
binding protein
long non coding rna
study protocol